INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17801, 202, 'Potassium gluconate', 'Gastrointestinal Diseases', 'The use of all solid oral formulations of potassium is contraindicated in patients with arrested or delayed gastrointestinal (GI) transit, whether due to structural, pathological, or pharmacological causes.  Potassium is irritating to the GI mucosa and may cause ulcerative and/or stenotic lesions during prolonged physical contact.  Based on spontaneous adverse reaction reports, the frequency of small bowel lesions associated with enteric-coated preparations of potassium chloride is 40 to 50 per 100,000 patient-years, while that for wax matrix controlled-release formulations is less than one per 100,000 patient years.  Esophageal ulceration has also been reported following administration of controlled-release formulations of potassium chloride in cardiac patients with esophageal compression due to enlarged left atrium.  Potassium supplementation should be administered as a liquid preparation or as an aqueous suspension in patients with esophageal obstruction and/or delayed gastrointestinal transit time.
Because of ulcerogenic effects, oral potassium should be administered cautiously in patients with peptic ulcers or other upper gastrointestinal diseases associated with inflammation, bleeding, or perforation.  Patients should be advised not to crush, chew, or break potassium tablets or capsules, and to take them with meals and a full glass of water or other liquid.  Potassium liquids should be diluted prior to consumption.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17802, 202, 'Potassium gluconate', 'Alkalosis', 'Hypokalemia in patients with metabolic or respiratory alkalosis should generally be treated with potassium chloride rather than an alkalinizing potassium salt (i.e. acetate, bicarbonate, citrate, or gluconate), since alkali therapy may exacerbate the condition.  In addition, hypochloremia may accompany alkalosis, which is best treated with potassium chloride.  Close monitoring of acid-base balance, serum electrolytes, electrocardiogram, and clinical status is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17803, 0, 'Pralidoxime', 'Myasthenia Gravis', 'Pralidoxime reactivates cholinesterase activity resulting in reduced levels of  acetylcholine and increased neuromuscular junction activity.  Treatment of organophosphate poisoning in patients myasthenia gravis with pralidoxime can precipitate a myasthenic crisis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17804, 0, 'Pralidoxime', 'Kidney Diseases', 'Pralidoxime is eliminated by the kidney.  Approximately 80% to 90% of pralidoxime is excreted in the urine as unchanged drug.  The serum concentration of pralidoxime is increased in patients with renal impairment.  Therapy with pralidoxime should be administered cautiously and dosages reduced in patients with compromised renal function.  Clinical monitoring of renal function and muscular activity is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17805, 3367, 'Potassium Iodide', 'Hyperthyroidism', 'The use of iodide salts has been associated with the exacerbation or precipitation of hyperthyroidism in patients previously euthyroid.  Induction of goiter has been reported in patients with hyperthyroidism.  Iodide salts should be administered cautiously in patients with hyperthyroidism.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17806, 25389, 'Potassium Iodide', 'Hyperthyroidism', 'The use of iodide salts has been associated with the exacerbation or precipitation of hyperthyroidism in patients previously euthyroid.  Induction of goiter has been reported in patients with hyperthyroidism.  Iodide salts should be administered cautiously in patients with hyperthyroidism.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17807, 3367, 'Potassium Iodide', 'Heart Diseases', 'Potassium iodide should not be used in patients that have nodular thyroid disease and heart disease.  Patients experiencing irregular heartbeats or chest pain should be instructed to stop treatment with potassium iodide.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17808, 25389, 'Potassium Iodide', 'Heart Diseases', 'Potassium iodide should not be used in patients that have nodular thyroid disease and heart disease.  Patients experiencing irregular heartbeats or chest pain should be instructed to stop treatment with potassium iodide.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17809, 3367, 'Potassium Iodide', 'Dermatitis Herpetiformis', 'Potassium iodide should not be used in patients that have or have ever had dermatitis herpetiformis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17810, 25389, 'Potassium Iodide', 'Dermatitis Herpetiformis', 'Potassium iodide should not be used in patients that have or have ever had dermatitis herpetiformis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17811, 3367, 'Potassium Iodide', 'Vasculitis', 'People who are allergic to iodide or have hypocomplementemic vasculitis should not take potassium iodide.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17812, 25389, 'Potassium Iodide', 'Vasculitis', 'People who are allergic to iodide or have hypocomplementemic vasculitis should not take potassium iodide.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17813, 1190, 'Azathioprine', 'Bone Marrow Failure Disorders', 'Azathioprine may cause severe leukopenia, thrombocytopenia, macrocytic anemia, severe bone marrow depression and, rarely, pure red cell aplasia.  Therapy with azathioprine should be administered cautiously in patients with bone marrow depression.  Hematological toxicities are dose related.  Caution and routine monitoring of blood counts and platelets is recommended.  Patients should report any unusual bleeding or bruising.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17814, 1193, 'Azathioprine', 'Bone Marrow Failure Disorders', 'Azathioprine may cause severe leukopenia, thrombocytopenia, macrocytic anemia, severe bone marrow depression and, rarely, pure red cell aplasia.  Therapy with azathioprine should be administered cautiously in patients with bone marrow depression.  Hematological toxicities are dose related.  Caution and routine monitoring of blood counts and platelets is recommended.  Patients should report any unusual bleeding or bruising.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17815, 5281, 'Azathioprine', 'Bone Marrow Failure Disorders', 'Azathioprine may cause severe leukopenia, thrombocytopenia, macrocytic anemia, severe bone marrow depression and, rarely, pure red cell aplasia.  Therapy with azathioprine should be administered cautiously in patients with bone marrow depression.  Hematological toxicities are dose related.  Caution and routine monitoring of blood counts and platelets is recommended.  Patients should report any unusual bleeding or bruising.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17816, 6430, 'Azathioprine', 'Bone Marrow Failure Disorders', 'Azathioprine may cause severe leukopenia, thrombocytopenia, macrocytic anemia, severe bone marrow depression and, rarely, pure red cell aplasia.  Therapy with azathioprine should be administered cautiously in patients with bone marrow depression.  Hematological toxicities are dose related.  Caution and routine monitoring of blood counts and platelets is recommended.  Patients should report any unusual bleeding or bruising.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17817, 14788, 'Azathioprine', 'Bone Marrow Failure Disorders', 'Azathioprine may cause severe leukopenia, thrombocytopenia, macrocytic anemia, severe bone marrow depression and, rarely, pure red cell aplasia.  Therapy with azathioprine should be administered cautiously in patients with bone marrow depression.  Hematological toxicities are dose related.  Caution and routine monitoring of blood counts and platelets is recommended.  Patients should report any unusual bleeding or bruising.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17818, 14790, 'Azathioprine', 'Bone Marrow Failure Disorders', 'Azathioprine may cause severe leukopenia, thrombocytopenia, macrocytic anemia, severe bone marrow depression and, rarely, pure red cell aplasia.  Therapy with azathioprine should be administered cautiously in patients with bone marrow depression.  Hematological toxicities are dose related.  Caution and routine monitoring of blood counts and platelets is recommended.  Patients should report any unusual bleeding or bruising.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17819, 14791, 'Azathioprine', 'Bone Marrow Failure Disorders', 'Azathioprine may cause severe leukopenia, thrombocytopenia, macrocytic anemia, severe bone marrow depression and, rarely, pure red cell aplasia.  Therapy with azathioprine should be administered cautiously in patients with bone marrow depression.  Hematological toxicities are dose related.  Caution and routine monitoring of blood counts and platelets is recommended.  Patients should report any unusual bleeding or bruising.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17820, 14793, 'Azathioprine', 'Bone Marrow Failure Disorders', 'Azathioprine may cause severe leukopenia, thrombocytopenia, macrocytic anemia, severe bone marrow depression and, rarely, pure red cell aplasia.  Therapy with azathioprine should be administered cautiously in patients with bone marrow depression.  Hematological toxicities are dose related.  Caution and routine monitoring of blood counts and platelets is recommended.  Patients should report any unusual bleeding or bruising.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17821, 17049, 'Azathioprine', 'Bone Marrow Failure Disorders', 'Azathioprine may cause severe leukopenia, thrombocytopenia, macrocytic anemia, severe bone marrow depression and, rarely, pure red cell aplasia.  Therapy with azathioprine should be administered cautiously in patients with bone marrow depression.  Hematological toxicities are dose related.  Caution and routine monitoring of blood counts and platelets is recommended.  Patients should report any unusual bleeding or bruising.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17822, 32468, 'Azathioprine', 'Bone Marrow Failure Disorders', 'Azathioprine may cause severe leukopenia, thrombocytopenia, macrocytic anemia, severe bone marrow depression and, rarely, pure red cell aplasia.  Therapy with azathioprine should be administered cautiously in patients with bone marrow depression.  Hematological toxicities are dose related.  Caution and routine monitoring of blood counts and platelets is recommended.  Patients should report any unusual bleeding or bruising.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17823, 32469, 'Azathioprine', 'Bone Marrow Failure Disorders', 'Azathioprine may cause severe leukopenia, thrombocytopenia, macrocytic anemia, severe bone marrow depression and, rarely, pure red cell aplasia.  Therapy with azathioprine should be administered cautiously in patients with bone marrow depression.  Hematological toxicities are dose related.  Caution and routine monitoring of blood counts and platelets is recommended.  Patients should report any unusual bleeding or bruising.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17824, 32470, 'Azathioprine', 'Bone Marrow Failure Disorders', 'Azathioprine may cause severe leukopenia, thrombocytopenia, macrocytic anemia, severe bone marrow depression and, rarely, pure red cell aplasia.  Therapy with azathioprine should be administered cautiously in patients with bone marrow depression.  Hematological toxicities are dose related.  Caution and routine monitoring of blood counts and platelets is recommended.  Patients should report any unusual bleeding or bruising.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17825, 1190, 'Azathioprine', 'Infections', 'Serious infections, including reactivation of latent infections have been reported with the use of azathioprine.  Cases of JC virus-associated infection resulting in progressive multifocal leukoencephalopathy (PML), sometimes fatal, have been reported in patients treated with immunosuppressants, including azathioprine.  A diagnosis of PML should be considered in any patient presenting with new-onset neurological manifestations and a consultation with a neurologist is recommended.  Consider reducing the amount of immunosuppression in patients who develop PML, and in transplant patients, consider the risk that the reduced immunosuppression represents to the graft.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17826, 1193, 'Azathioprine', 'Infections', 'Serious infections, including reactivation of latent infections have been reported with the use of azathioprine.  Cases of JC virus-associated infection resulting in progressive multifocal leukoencephalopathy (PML), sometimes fatal, have been reported in patients treated with immunosuppressants, including azathioprine.  A diagnosis of PML should be considered in any patient presenting with new-onset neurological manifestations and a consultation with a neurologist is recommended.  Consider reducing the amount of immunosuppression in patients who develop PML, and in transplant patients, consider the risk that the reduced immunosuppression represents to the graft.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17827, 5281, 'Azathioprine', 'Infections', 'Serious infections, including reactivation of latent infections have been reported with the use of azathioprine.  Cases of JC virus-associated infection resulting in progressive multifocal leukoencephalopathy (PML), sometimes fatal, have been reported in patients treated with immunosuppressants, including azathioprine.  A diagnosis of PML should be considered in any patient presenting with new-onset neurological manifestations and a consultation with a neurologist is recommended.  Consider reducing the amount of immunosuppression in patients who develop PML, and in transplant patients, consider the risk that the reduced immunosuppression represents to the graft.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17828, 6430, 'Azathioprine', 'Infections', 'Serious infections, including reactivation of latent infections have been reported with the use of azathioprine.  Cases of JC virus-associated infection resulting in progressive multifocal leukoencephalopathy (PML), sometimes fatal, have been reported in patients treated with immunosuppressants, including azathioprine.  A diagnosis of PML should be considered in any patient presenting with new-onset neurological manifestations and a consultation with a neurologist is recommended.  Consider reducing the amount of immunosuppression in patients who develop PML, and in transplant patients, consider the risk that the reduced immunosuppression represents to the graft.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17829, 14788, 'Azathioprine', 'Infections', 'Serious infections, including reactivation of latent infections have been reported with the use of azathioprine.  Cases of JC virus-associated infection resulting in progressive multifocal leukoencephalopathy (PML), sometimes fatal, have been reported in patients treated with immunosuppressants, including azathioprine.  A diagnosis of PML should be considered in any patient presenting with new-onset neurological manifestations and a consultation with a neurologist is recommended.  Consider reducing the amount of immunosuppression in patients who develop PML, and in transplant patients, consider the risk that the reduced immunosuppression represents to the graft.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17830, 14790, 'Azathioprine', 'Infections', 'Serious infections, including reactivation of latent infections have been reported with the use of azathioprine.  Cases of JC virus-associated infection resulting in progressive multifocal leukoencephalopathy (PML), sometimes fatal, have been reported in patients treated with immunosuppressants, including azathioprine.  A diagnosis of PML should be considered in any patient presenting with new-onset neurological manifestations and a consultation with a neurologist is recommended.  Consider reducing the amount of immunosuppression in patients who develop PML, and in transplant patients, consider the risk that the reduced immunosuppression represents to the graft.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17831, 14791, 'Azathioprine', 'Infections', 'Serious infections, including reactivation of latent infections have been reported with the use of azathioprine.  Cases of JC virus-associated infection resulting in progressive multifocal leukoencephalopathy (PML), sometimes fatal, have been reported in patients treated with immunosuppressants, including azathioprine.  A diagnosis of PML should be considered in any patient presenting with new-onset neurological manifestations and a consultation with a neurologist is recommended.  Consider reducing the amount of immunosuppression in patients who develop PML, and in transplant patients, consider the risk that the reduced immunosuppression represents to the graft.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17832, 14793, 'Azathioprine', 'Infections', 'Serious infections, including reactivation of latent infections have been reported with the use of azathioprine.  Cases of JC virus-associated infection resulting in progressive multifocal leukoencephalopathy (PML), sometimes fatal, have been reported in patients treated with immunosuppressants, including azathioprine.  A diagnosis of PML should be considered in any patient presenting with new-onset neurological manifestations and a consultation with a neurologist is recommended.  Consider reducing the amount of immunosuppression in patients who develop PML, and in transplant patients, consider the risk that the reduced immunosuppression represents to the graft.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17833, 17049, 'Azathioprine', 'Infections', 'Serious infections, including reactivation of latent infections have been reported with the use of azathioprine.  Cases of JC virus-associated infection resulting in progressive multifocal leukoencephalopathy (PML), sometimes fatal, have been reported in patients treated with immunosuppressants, including azathioprine.  A diagnosis of PML should be considered in any patient presenting with new-onset neurological manifestations and a consultation with a neurologist is recommended.  Consider reducing the amount of immunosuppression in patients who develop PML, and in transplant patients, consider the risk that the reduced immunosuppression represents to the graft.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17834, 32468, 'Azathioprine', 'Infections', 'Serious infections, including reactivation of latent infections have been reported with the use of azathioprine.  Cases of JC virus-associated infection resulting in progressive multifocal leukoencephalopathy (PML), sometimes fatal, have been reported in patients treated with immunosuppressants, including azathioprine.  A diagnosis of PML should be considered in any patient presenting with new-onset neurological manifestations and a consultation with a neurologist is recommended.  Consider reducing the amount of immunosuppression in patients who develop PML, and in transplant patients, consider the risk that the reduced immunosuppression represents to the graft.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17835, 32469, 'Azathioprine', 'Infections', 'Serious infections, including reactivation of latent infections have been reported with the use of azathioprine.  Cases of JC virus-associated infection resulting in progressive multifocal leukoencephalopathy (PML), sometimes fatal, have been reported in patients treated with immunosuppressants, including azathioprine.  A diagnosis of PML should be considered in any patient presenting with new-onset neurological manifestations and a consultation with a neurologist is recommended.  Consider reducing the amount of immunosuppression in patients who develop PML, and in transplant patients, consider the risk that the reduced immunosuppression represents to the graft.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17836, 32470, 'Azathioprine', 'Infections', 'Serious infections, including reactivation of latent infections have been reported with the use of azathioprine.  Cases of JC virus-associated infection resulting in progressive multifocal leukoencephalopathy (PML), sometimes fatal, have been reported in patients treated with immunosuppressants, including azathioprine.  A diagnosis of PML should be considered in any patient presenting with new-onset neurological manifestations and a consultation with a neurologist is recommended.  Consider reducing the amount of immunosuppression in patients who develop PML, and in transplant patients, consider the risk that the reduced immunosuppression represents to the graft.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17837, 1190, 'Azathioprine', 'Kidney Diseases', 'Azathioprine may accumulate in patients with impaired renal function.  Therapy with azathioprine should be administered cautiously and may need dosage reduction in patients with impaired renal function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17838, 1193, 'Azathioprine', 'Kidney Diseases', 'Azathioprine may accumulate in patients with impaired renal function.  Therapy with azathioprine should be administered cautiously and may need dosage reduction in patients with impaired renal function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17839, 5281, 'Azathioprine', 'Kidney Diseases', 'Azathioprine may accumulate in patients with impaired renal function.  Therapy with azathioprine should be administered cautiously and may need dosage reduction in patients with impaired renal function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17840, 6430, 'Azathioprine', 'Kidney Diseases', 'Azathioprine may accumulate in patients with impaired renal function.  Therapy with azathioprine should be administered cautiously and may need dosage reduction in patients with impaired renal function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17841, 14788, 'Azathioprine', 'Kidney Diseases', 'Azathioprine may accumulate in patients with impaired renal function.  Therapy with azathioprine should be administered cautiously and may need dosage reduction in patients with impaired renal function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17842, 14790, 'Azathioprine', 'Kidney Diseases', 'Azathioprine may accumulate in patients with impaired renal function.  Therapy with azathioprine should be administered cautiously and may need dosage reduction in patients with impaired renal function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17843, 14791, 'Azathioprine', 'Kidney Diseases', 'Azathioprine may accumulate in patients with impaired renal function.  Therapy with azathioprine should be administered cautiously and may need dosage reduction in patients with impaired renal function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17844, 14793, 'Azathioprine', 'Kidney Diseases', 'Azathioprine may accumulate in patients with impaired renal function.  Therapy with azathioprine should be administered cautiously and may need dosage reduction in patients with impaired renal function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17845, 17049, 'Azathioprine', 'Kidney Diseases', 'Azathioprine may accumulate in patients with impaired renal function.  Therapy with azathioprine should be administered cautiously and may need dosage reduction in patients with impaired renal function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17846, 32468, 'Azathioprine', 'Kidney Diseases', 'Azathioprine may accumulate in patients with impaired renal function.  Therapy with azathioprine should be administered cautiously and may need dosage reduction in patients with impaired renal function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17847, 32469, 'Azathioprine', 'Kidney Diseases', 'Azathioprine may accumulate in patients with impaired renal function.  Therapy with azathioprine should be administered cautiously and may need dosage reduction in patients with impaired renal function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17848, 32470, 'Azathioprine', 'Kidney Diseases', 'Azathioprine may accumulate in patients with impaired renal function.  Therapy with azathioprine should be administered cautiously and may need dosage reduction in patients with impaired renal function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17849, 1190, 'Azathioprine', 'Liver Diseases', 'Azathioprine is metabolically converted to the pharmacologically active 6-mercaptopurine (6-MP).  Conversion to 6-MP and metabolism of 6-MP may be impaired in patients with liver disease.  Therapy with azathioprine should be administered cautiously in patients with liver disease.  Monitoring liver function is recommended in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17850, 1193, 'Azathioprine', 'Liver Diseases', 'Azathioprine is metabolically converted to the pharmacologically active 6-mercaptopurine (6-MP).  Conversion to 6-MP and metabolism of 6-MP may be impaired in patients with liver disease.  Therapy with azathioprine should be administered cautiously in patients with liver disease.  Monitoring liver function is recommended in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17851, 5281, 'Azathioprine', 'Liver Diseases', 'Azathioprine is metabolically converted to the pharmacologically active 6-mercaptopurine (6-MP).  Conversion to 6-MP and metabolism of 6-MP may be impaired in patients with liver disease.  Therapy with azathioprine should be administered cautiously in patients with liver disease.  Monitoring liver function is recommended in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17852, 6430, 'Azathioprine', 'Liver Diseases', 'Azathioprine is metabolically converted to the pharmacologically active 6-mercaptopurine (6-MP).  Conversion to 6-MP and metabolism of 6-MP may be impaired in patients with liver disease.  Therapy with azathioprine should be administered cautiously in patients with liver disease.  Monitoring liver function is recommended in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17853, 14788, 'Azathioprine', 'Liver Diseases', 'Azathioprine is metabolically converted to the pharmacologically active 6-mercaptopurine (6-MP).  Conversion to 6-MP and metabolism of 6-MP may be impaired in patients with liver disease.  Therapy with azathioprine should be administered cautiously in patients with liver disease.  Monitoring liver function is recommended in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17854, 14790, 'Azathioprine', 'Liver Diseases', 'Azathioprine is metabolically converted to the pharmacologically active 6-mercaptopurine (6-MP).  Conversion to 6-MP and metabolism of 6-MP may be impaired in patients with liver disease.  Therapy with azathioprine should be administered cautiously in patients with liver disease.  Monitoring liver function is recommended in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17855, 14791, 'Azathioprine', 'Liver Diseases', 'Azathioprine is metabolically converted to the pharmacologically active 6-mercaptopurine (6-MP).  Conversion to 6-MP and metabolism of 6-MP may be impaired in patients with liver disease.  Therapy with azathioprine should be administered cautiously in patients with liver disease.  Monitoring liver function is recommended in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17856, 14793, 'Azathioprine', 'Liver Diseases', 'Azathioprine is metabolically converted to the pharmacologically active 6-mercaptopurine (6-MP).  Conversion to 6-MP and metabolism of 6-MP may be impaired in patients with liver disease.  Therapy with azathioprine should be administered cautiously in patients with liver disease.  Monitoring liver function is recommended in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17857, 17049, 'Azathioprine', 'Liver Diseases', 'Azathioprine is metabolically converted to the pharmacologically active 6-mercaptopurine (6-MP).  Conversion to 6-MP and metabolism of 6-MP may be impaired in patients with liver disease.  Therapy with azathioprine should be administered cautiously in patients with liver disease.  Monitoring liver function is recommended in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17858, 32468, 'Azathioprine', 'Liver Diseases', 'Azathioprine is metabolically converted to the pharmacologically active 6-mercaptopurine (6-MP).  Conversion to 6-MP and metabolism of 6-MP may be impaired in patients with liver disease.  Therapy with azathioprine should be administered cautiously in patients with liver disease.  Monitoring liver function is recommended in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17859, 32469, 'Azathioprine', 'Liver Diseases', 'Azathioprine is metabolically converted to the pharmacologically active 6-mercaptopurine (6-MP).  Conversion to 6-MP and metabolism of 6-MP may be impaired in patients with liver disease.  Therapy with azathioprine should be administered cautiously in patients with liver disease.  Monitoring liver function is recommended in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17860, 32470, 'Azathioprine', 'Liver Diseases', 'Azathioprine is metabolically converted to the pharmacologically active 6-mercaptopurine (6-MP).  Conversion to 6-MP and metabolism of 6-MP may be impaired in patients with liver disease.  Therapy with azathioprine should be administered cautiously in patients with liver disease.  Monitoring liver function is recommended in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17861, 0, 'Plecanatide', 'Dehydration', 'Plecanatide should be used with caution in dehydrated patients and patients with severe diarrhea.  Plecanatide is contraindicated in patients less than 6 years of age as these patients may be more likely to develop severe diarrhea and its potentially serious consequences.  Care is recommended when using this agent in adult patients with electrolyte abnormalities or with severe diarrhea.  It is recommended to suspend dosing and rehydrate the patient if such symptoms occur during therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17862, 0, 'Plecanatide', 'Intestinal Obstruction', 'The use of plecanatide is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17863, 2559, 'Acetazolamide', 'Bone Marrow Failure Disorders', 'The use of carbonic anhydrase inhibitors may rarely cause bone marrow suppression and blood dyscrasias at recommended dosages.  Aplastic anemia, thrombocytopenia or thrombocytopenia purpura, leukopenia, agranulocytosis, and hemolytic anemia have been reported.  Extreme caution should be exercised if carbonic anhydrase inhibitors are administered to patients with these preexisting conditions.  A baseline CBC and platelet count is recommended, as well as monitoring at regular intervals during therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17864, 3601, 'Acetazolamide', 'Bone Marrow Failure Disorders', 'The use of carbonic anhydrase inhibitors may rarely cause bone marrow suppression and blood dyscrasias at recommended dosages.  Aplastic anemia, thrombocytopenia or thrombocytopenia purpura, leukopenia, agranulocytosis, and hemolytic anemia have been reported.  Extreme caution should be exercised if carbonic anhydrase inhibitors are administered to patients with these preexisting conditions.  A baseline CBC and platelet count is recommended, as well as monitoring at regular intervals during therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17865, 2559, 'Acetazolamide', 'Adrenal Insufficiency', 'The use of carbonic anhydrase inhibitors is contraindicated in patients with adrenal insufficiency.  The carbonic anhydrase inhibitor effect may exacerbate electrolyte problems that can occur with primary adrenal insufficiency.  Extreme caution should be exercised if a carbonic anhydrase inhibitor is administered to these patients.  Monitoring electrolyte levels is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17866, 3601, 'Acetazolamide', 'Adrenal Insufficiency', 'The use of carbonic anhydrase inhibitors is contraindicated in patients with adrenal insufficiency.  The carbonic anhydrase inhibitor effect may exacerbate electrolyte problems that can occur with primary adrenal insufficiency.  Extreme caution should be exercised if a carbonic anhydrase inhibitor is administered to these patients.  Monitoring electrolyte levels is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17867, 2559, 'Acetazolamide', 'Glaucoma, Angle-Closure', 'The use of carbonic anhydrase inhibitors is contraindicated in patients with closed-angle glaucoma.  Carbonic anhydrase inhibitors may mask worsening glaucoma due to decreased intraocular pressure.  Extreme caution should be exercised if carbonic anhydrase inhibitors is administered to these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17868, 3601, 'Acetazolamide', 'Glaucoma, Angle-Closure', 'The use of carbonic anhydrase inhibitors is contraindicated in patients with closed-angle glaucoma.  Carbonic anhydrase inhibitors may mask worsening glaucoma due to decreased intraocular pressure.  Extreme caution should be exercised if carbonic anhydrase inhibitors is administered to these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17869, 2559, 'Acetazolamide', 'Hypokalemia', 'The use of carbonic anhydrase inhibitors is contraindicated in patients with hypokalemia .  Carbonic anhydrase inhibitors may cause increased potassium excretion.  Extreme caution should be exercised if a carbonic anhydrase inhibitor is administered and monitoring electrolyte levels is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17870, 3601, 'Acetazolamide', 'Hypokalemia', 'The use of carbonic anhydrase inhibitors is contraindicated in patients with hypokalemia .  Carbonic anhydrase inhibitors may cause increased potassium excretion.  Extreme caution should be exercised if a carbonic anhydrase inhibitor is administered and monitoring electrolyte levels is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17871, 2559, 'Acetazolamide', 'Hyponatremia', 'The use of carbonic anhydrase inhibitors is contraindicated in patients with hyponatremia .  Carbonic anhydrase inhibitors may cause sodium excretion.  Extreme caution should be exercised if a carbonic anhydrase inhibitor is administered and monitoring electrolyte levels is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17872, 3601, 'Acetazolamide', 'Hyponatremia', 'The use of carbonic anhydrase inhibitors is contraindicated in patients with hyponatremia .  Carbonic anhydrase inhibitors may cause sodium excretion.  Extreme caution should be exercised if a carbonic anhydrase inhibitor is administered and monitoring electrolyte levels is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17873, 2559, 'Acetazolamide', 'Kidney Diseases', 'The use of some carbonic anhydrase inhibitors is contraindicated in patients with severe kidney disease.  Dysuria, crystalluria, renal colic, and other renal lesions have been reported during therapy with carbonic anhydrase inhibitors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17874, 3601, 'Acetazolamide', 'Kidney Diseases', 'The use of some carbonic anhydrase inhibitors is contraindicated in patients with severe kidney disease.  Dysuria, crystalluria, renal colic, and other renal lesions have been reported during therapy with carbonic anhydrase inhibitors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17875, 2559, 'Acetazolamide', 'Liver Failure', 'The use of carbonic anhydrase inhibitors is contraindicated in patients with marked liver disease or cirrhosis.  Carbonic anhydrase inhibitors increase the risk of developing hepatic encephalopathy in these patients.  Extreme caution should be exercised if carbonic anhydrase inhibitors are administered in patients with mild to moderate liver disease as the clearance of the drug can be decreased.  A dose reduction might be needed and monitoring of the liver function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17876, 3601, 'Acetazolamide', 'Liver Failure', 'The use of carbonic anhydrase inhibitors is contraindicated in patients with marked liver disease or cirrhosis.  Carbonic anhydrase inhibitors increase the risk of developing hepatic encephalopathy in these patients.  Extreme caution should be exercised if carbonic anhydrase inhibitors are administered in patients with mild to moderate liver disease as the clearance of the drug can be decreased.  A dose reduction might be needed and monitoring of the liver function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17877, 2559, 'Acetazolamide', 'Acidosis, Respiratory', 'Carbonic anhydrase inhibitors may exacerbate pulmonary disease in patients with elevated pCO2 levels.  Respiratory acidosis may be precipitated or increased in these patients.  Therapy with carbonic anhydrase inhibitors should be administered cautiously in patients with respiratory acidosis, and conditions where alveolar ventilation may be impaired (pulmonary obstruction, emphysema, etc) and can precipitate or aggravate acidosis.  Respiratory status should be monitored during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17878, 3601, 'Acetazolamide', 'Acidosis, Respiratory', 'Carbonic anhydrase inhibitors may exacerbate pulmonary disease in patients with elevated pCO2 levels.  Respiratory acidosis may be precipitated or increased in these patients.  Therapy with carbonic anhydrase inhibitors should be administered cautiously in patients with respiratory acidosis, and conditions where alveolar ventilation may be impaired (pulmonary obstruction, emphysema, etc) and can precipitate or aggravate acidosis.  Respiratory status should be monitored during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17879, 2559, 'Acetazolamide', 'Diabetes Mellitus', 'Elevation of blood glucose, possibly caused by hypokalemia, and glycosuria have been reported rarely in diabetics receiving carbonic anhydrase inhibitors.  Therapy with carbonic anhydrase inhibitors should be administered cautiously in patients with diabetes mellitus.  Routine glucose monitoring is recommended during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17880, 3601, 'Acetazolamide', 'Diabetes Mellitus', 'Elevation of blood glucose, possibly caused by hypokalemia, and glycosuria have been reported rarely in diabetics receiving carbonic anhydrase inhibitors.  Therapy with carbonic anhydrase inhibitors should be administered cautiously in patients with diabetes mellitus.  Routine glucose monitoring is recommended during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17881, 2559, 'Acetazolamide', 'Gout', 'Uric acid excretion is decreased during therapy with carbonic anhydrase inhibitors, and gout may be exacerbated.  Therapy with carbonic anhydrase inhibitors should be administered cautiously in patients with gout.  Elevated serum uric acid levels return to normal when the drug is discontinued.  Monitoring of uric acid levels is recommended in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17882, 3601, 'Acetazolamide', 'Gout', 'Uric acid excretion is decreased during therapy with carbonic anhydrase inhibitors, and gout may be exacerbated.  Therapy with carbonic anhydrase inhibitors should be administered cautiously in patients with gout.  Elevated serum uric acid levels return to normal when the drug is discontinued.  Monitoring of uric acid levels is recommended in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17883, 2559, 'Acetazolamide', 'Acidosis', 'Reduced plasma bicarbonate levels and, in some instances, elevated plasma chloride levels may result in metabolic acidosis during long-term therapy with carbonic anhydrase inhibitors.  Therapy with carbonic anhydrase inhibitors should be administered cautiously in patients with metabolic or hyperchloremic acidosis or with conditions that predispose to acidosis (renal disease, severe respiratory disorders, diarrhea).  The measurement of baseline and periodic serum bicarbonate is recommended.  If metabolic acidosis develops (it may be corrected by administration of sodium bicarbonate), and persists, a dose reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17884, 3601, 'Acetazolamide', 'Acidosis', 'Reduced plasma bicarbonate levels and, in some instances, elevated plasma chloride levels may result in metabolic acidosis during long-term therapy with carbonic anhydrase inhibitors.  Therapy with carbonic anhydrase inhibitors should be administered cautiously in patients with metabolic or hyperchloremic acidosis or with conditions that predispose to acidosis (renal disease, severe respiratory disorders, diarrhea).  The measurement of baseline and periodic serum bicarbonate is recommended.  If metabolic acidosis develops (it may be corrected by administration of sodium bicarbonate), and persists, a dose reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17885, 19302, 'Pralatrexate', 'Liver Failure', 'The safety, efficacy and pharmacokinetics of pralatrexate have not been evaluated in patients with hepatic impairment.  Additionally, this drug can cause hepatotoxicity and liver function test abnormalities, which might require dose modification or discontinuation.  Caution and monitoring is advised.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17886, 19302, 'Pralatrexate', 'Kidney Diseases', 'Patients with moderate to severe renal function impairment may be at greater risk of toxicity due to increased exposure.  Patients should be monitored for renal function and toxicity and dosage should be adjusted accordingly.  For patients with severe renal impairment (GFR 15 to <30), the recommended dose of pralatrexate is 15 mg/m2.  Avoid the use of pralatrexate in patients with ESRD undergoing dialysis, unless the potential effect justifies the potential risk.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17887, 0, 'Prasugrel', 'Hemorrhage', 'Prasugrel is contraindicated in patients with active pathological bleeding such as peptic ulcer or intracranial hemorrhage, as this agent increases the risk of fatal bleeding.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17888, 0, 'Prasugrel', 'Coronary Artery Disease', 'Prasugrel is contraindicated in patients with a history of prior transient ischemic attack (TIA) or stroke.  Patients who experience a stroke or TIA while on prasugrel generally should have therapy discontinued.  The risk of bleeding is increased in patients receiving prasugrel who undergo coronary artery bypass graft.  If possible, prasugrel should be discontinued at least 7 days prior to the procedure.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17889, 0, 'Prasugrel', 'Liver Diseases', 'No dosage adjustment is necessary for patients with renal impairment.  No dosage adjustment is necessary in patients with mild to moderate hepatic impairment.  Caution should be exercised in patients with end-stage renal disease and those with severe hepatic disease as such patients are generally at higher risk of bleeding.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17890, 7403, 'Pravastatin', 'Liver Diseases', 'The use of HMG-CoA reductase inhibitors is contraindicated in patients with active liver disease or unexplained, persistent elevations of serum transaminases.  HMG-CoA reductase inhibitors are extensively metabolized by the liver.  Decreased drug metabolism may lead to accumulation and increased risk of toxicity, including biochemical abnormalities of liver function and, rarely, jaundice, hepatitis, cirrhosis, fatty change in the liver, and fulminant hepatic necrosis.  Therapy with HMG-CoA reductase inhibitors should be administered cautiously in patients with a history of liver disease and/or heavy alcohol use.  A lower initial dosage may be appropriate, and clinical monitoring of liver transaminase levels according to the individual product package labeling is recommended.  Patients who develop elevated  ALT or AST levels during therapy should be monitored until abnormalities resolve.  If an increase above 3 times the upper limit of normal persists, consideration should be given to a reduction in dosage or withdrawal of therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17891, 7405, 'Pravastatin', 'Liver Diseases', 'The use of HMG-CoA reductase inhibitors is contraindicated in patients with active liver disease or unexplained, persistent elevations of serum transaminases.  HMG-CoA reductase inhibitors are extensively metabolized by the liver.  Decreased drug metabolism may lead to accumulation and increased risk of toxicity, including biochemical abnormalities of liver function and, rarely, jaundice, hepatitis, cirrhosis, fatty change in the liver, and fulminant hepatic necrosis.  Therapy with HMG-CoA reductase inhibitors should be administered cautiously in patients with a history of liver disease and/or heavy alcohol use.  A lower initial dosage may be appropriate, and clinical monitoring of liver transaminase levels according to the individual product package labeling is recommended.  Patients who develop elevated  ALT or AST levels during therapy should be monitored until abnormalities resolve.  If an increase above 3 times the upper limit of normal persists, consideration should be given to a reduction in dosage or withdrawal of therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17892, 16265, 'Pravastatin', 'Liver Diseases', 'The use of HMG-CoA reductase inhibitors is contraindicated in patients with active liver disease or unexplained, persistent elevations of serum transaminases.  HMG-CoA reductase inhibitors are extensively metabolized by the liver.  Decreased drug metabolism may lead to accumulation and increased risk of toxicity, including biochemical abnormalities of liver function and, rarely, jaundice, hepatitis, cirrhosis, fatty change in the liver, and fulminant hepatic necrosis.  Therapy with HMG-CoA reductase inhibitors should be administered cautiously in patients with a history of liver disease and/or heavy alcohol use.  A lower initial dosage may be appropriate, and clinical monitoring of liver transaminase levels according to the individual product package labeling is recommended.  Patients who develop elevated  ALT or AST levels during therapy should be monitored until abnormalities resolve.  If an increase above 3 times the upper limit of normal persists, consideration should be given to a reduction in dosage or withdrawal of therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17893, 21898, 'Pravastatin', 'Liver Diseases', 'The use of HMG-CoA reductase inhibitors is contraindicated in patients with active liver disease or unexplained, persistent elevations of serum transaminases.  HMG-CoA reductase inhibitors are extensively metabolized by the liver.  Decreased drug metabolism may lead to accumulation and increased risk of toxicity, including biochemical abnormalities of liver function and, rarely, jaundice, hepatitis, cirrhosis, fatty change in the liver, and fulminant hepatic necrosis.  Therapy with HMG-CoA reductase inhibitors should be administered cautiously in patients with a history of liver disease and/or heavy alcohol use.  A lower initial dosage may be appropriate, and clinical monitoring of liver transaminase levels according to the individual product package labeling is recommended.  Patients who develop elevated  ALT or AST levels during therapy should be monitored until abnormalities resolve.  If an increase above 3 times the upper limit of normal persists, consideration should be given to a reduction in dosage or withdrawal of therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17894, 7403, 'Pravastatin', 'Rhabdomyolysis', 'Severe myopathy, including rhabdomyolysis with acute renal failure secondary to myoglobinuria, has been reported rarely with the use of HMG-CoA reductase inhibitors.  The myopathy may be dose-related and is characterized by muscle aches and/or weakness in conjunction with increases in creatine phosphokinase (CPK) values exceeding 10 times the upper limit of normal.  Therapy with HMG-CoA reductase inhibitors should be administered cautiously in patients with preexisting myopathy, in those with predisposing factors for myopathy or with a history of myoneural disorder, since it may delay the recognition or confound the diagnosis of a drug-induced musculoskeletal effect.  Patients should be advised to report promptly any unusual muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever.  Periodic CPK determinations may be considered in some patients, although the value of such monitoring is uncertain.  HMG-CoA reductase inhibitor therapy should be withdrawn if markedly elevated CPK levels occur or if drug-related myopathy is diagnosed or suspected.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17895, 7405, 'Pravastatin', 'Rhabdomyolysis', 'Severe myopathy, including rhabdomyolysis with acute renal failure secondary to myoglobinuria, has been reported rarely with the use of HMG-CoA reductase inhibitors.  The myopathy may be dose-related and is characterized by muscle aches and/or weakness in conjunction with increases in creatine phosphokinase (CPK) values exceeding 10 times the upper limit of normal.  Therapy with HMG-CoA reductase inhibitors should be administered cautiously in patients with preexisting myopathy, in those with predisposing factors for myopathy or with a history of myoneural disorder, since it may delay the recognition or confound the diagnosis of a drug-induced musculoskeletal effect.  Patients should be advised to report promptly any unusual muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever.  Periodic CPK determinations may be considered in some patients, although the value of such monitoring is uncertain.  HMG-CoA reductase inhibitor therapy should be withdrawn if markedly elevated CPK levels occur or if drug-related myopathy is diagnosed or suspected.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17896, 16265, 'Pravastatin', 'Rhabdomyolysis', 'Severe myopathy, including rhabdomyolysis with acute renal failure secondary to myoglobinuria, has been reported rarely with the use of HMG-CoA reductase inhibitors.  The myopathy may be dose-related and is characterized by muscle aches and/or weakness in conjunction with increases in creatine phosphokinase (CPK) values exceeding 10 times the upper limit of normal.  Therapy with HMG-CoA reductase inhibitors should be administered cautiously in patients with preexisting myopathy, in those with predisposing factors for myopathy or with a history of myoneural disorder, since it may delay the recognition or confound the diagnosis of a drug-induced musculoskeletal effect.  Patients should be advised to report promptly any unusual muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever.  Periodic CPK determinations may be considered in some patients, although the value of such monitoring is uncertain.  HMG-CoA reductase inhibitor therapy should be withdrawn if markedly elevated CPK levels occur or if drug-related myopathy is diagnosed or suspected.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17897, 21898, 'Pravastatin', 'Rhabdomyolysis', 'Severe myopathy, including rhabdomyolysis with acute renal failure secondary to myoglobinuria, has been reported rarely with the use of HMG-CoA reductase inhibitors.  The myopathy may be dose-related and is characterized by muscle aches and/or weakness in conjunction with increases in creatine phosphokinase (CPK) values exceeding 10 times the upper limit of normal.  Therapy with HMG-CoA reductase inhibitors should be administered cautiously in patients with preexisting myopathy, in those with predisposing factors for myopathy or with a history of myoneural disorder, since it may delay the recognition or confound the diagnosis of a drug-induced musculoskeletal effect.  Patients should be advised to report promptly any unusual muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever.  Periodic CPK determinations may be considered in some patients, although the value of such monitoring is uncertain.  HMG-CoA reductase inhibitor therapy should be withdrawn if markedly elevated CPK levels occur or if drug-related myopathy is diagnosed or suspected.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17898, 7403, 'Pravastatin', 'Kidney Diseases', 'Pravastatin is partially eliminated by the kidney.  Drug and/or metabolite accumulation may occur in patients with significant renal impairment, which may increase the risk of adverse effects, including hepatic and musculoskeletal toxicities.  Therapy with pravastatin should be administered cautiously in patients with severely impaired renal function.  A lower initial dosage may be appropriate, accompanied by close clinical monitoring.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17899, 7405, 'Pravastatin', 'Kidney Diseases', 'Pravastatin is partially eliminated by the kidney.  Drug and/or metabolite accumulation may occur in patients with significant renal impairment, which may increase the risk of adverse effects, including hepatic and musculoskeletal toxicities.  Therapy with pravastatin should be administered cautiously in patients with severely impaired renal function.  A lower initial dosage may be appropriate, accompanied by close clinical monitoring.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17900, 16265, 'Pravastatin', 'Kidney Diseases', 'Pravastatin is partially eliminated by the kidney.  Drug and/or metabolite accumulation may occur in patients with significant renal impairment, which may increase the risk of adverse effects, including hepatic and musculoskeletal toxicities.  Therapy with pravastatin should be administered cautiously in patients with severely impaired renal function.  A lower initial dosage may be appropriate, accompanied by close clinical monitoring.', '3', '', 'DDInter', 0);
